الصفحة الرئيسية>>Signaling Pathways>> Antibody-drug Conjugate/ADC Related>> ADC Cytotoxin>>MMAD-d8

MMAD-d8 (Synonyms: Demethyldolastatin 10-d8; Monomethylauristatin D-d8; Monomethyl Dolastatin 10-d8)

رقم الكتالوجGC63775

D8-MMAD هو شكل ديوتيد من MMAD ، وهو عامل تعطيل الأنابيب الدقيقة

Products are for research use only. Not for human use. We do not sell to patients.

MMAD-d8 التركيب الكيميائي

الحجم السعر المخزون الكميّة
1 mg
990٫00
متوفر
5 mg
2250٫00
متوفر
10 mg
4230٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

D8-MMAD is a deuterated form of MMAD, which is a microtubule disrupting agent.

MMAD (Monomethyl Dolastatin 10) is coupled through a stable oxime-ligation process to yield several near-homogenous antibody-drug conjugates (ADCs) with a drug-to-antibody ratio of ~2.0. The resulting conjugates demonstrate good pharmacokinetic properties, potent in vitro cytotoxic activity against HER2+ cancer cells. When compared with ADCs prepared by cysteine alkylation following native interchain disulfide reduction, site-specific unnatural-amino-acid-based ADCs are shown to have increased in vitro cytotoxicity[1].

The resulting antibody-drug conjugates (ADCs) demonstrate complete tumour regression in rodents. They also have an improved toxicology profile in rats[1].

[1]. Chudasama V, et al. Recent advances in the construction of antibody-drug conjugates. Nat Chem. 2016 Feb;8(2):114-9.

مراجعات

Review for MMAD-d8

Average Rating: 5 ★★★★★ (Based on Reviews and 22 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for MMAD-d8

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.